Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action (Q37285921)

19 August 2017

1 reference

title

Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action (English)

1 reference

19 August 2017

0 references

0 references

Antonio Waldo Zuardi

1 reference

19 August 2017

publication date

1 September 2008

1 reference

Brazilian Journal of Psychiatry

19 August 2017

published in

1 reference

19 August 2017

1 reference

19 August 2017

1 reference

19 August 2017

page(s)

271-280

1 reference

Structure of Cannabidiol, a Product Isolated from the Marihuana Extract of Minnesota Wild Hemp. I

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000300015

Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000300015

A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000300015

Discovery and characterization of endogenous cannabinoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000300015

Cannabidiol: an overview of some chemical and pharmacological aspects. Part I: chemical aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000300015

Cannabidiol: an overview of some pharmacological aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000300015

Cannabidiol--recent advances

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000300015

Stimulus Characteristics of Marihuana Components

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000300015

The content of (-) 9 -trans-tetrahydrocannabinol ( 9 -thc) does not explain all biological activity of some Brazilian marihuana samples.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000300015

Cannabidiol interferes with the effects of Δ9-tetrahydrocannabinol in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000300015

Influence of cannabidiol on delta-9-tetrahydrocannabinol effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000300015

Effect of cannabis and certain of its constituents on pentobarbitone sleeping time and phenazone metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000300015

Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of Delta9-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000300015

Letter: Cannabidiol and Cannabis sativa extract protect mice and rats against convulsive agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000300015

Hypnoticlike effects of cannabidiol in the rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000300015

Effect of Delta-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000300015

Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000300015

Cannabidiol, a constituent of Cannabis sativa, modulates sleep in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000300015

Open label evaluation of cannabidiol in dystonic movement disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000300015

Controlled clinical trial of cannabidiol in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000300015

Antianxiety effect of cannabidiol in the elevated plus-maze

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000300015

Anxiolytic-like effect of cannabidiol in the rat Vogel conflict test

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000300015

Effects of cannabidiol (CBD) on regional cerebral blood flow

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000300015

Cannabis-associated psychosis with hypomanic features

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000300015

Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000300015

Cannabidiol reverses MK-801-induced disruption of prepulse inhibition in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000300015

Reduced binocular depth inversion in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000300015

Different effects of nabilone and cannabidiol on binocular depth inversion in Man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000300015

Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000300015

Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000300015

Cannabidiol monotherapy for treatment-resistant schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000300015

Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000300015

Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000300015

Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoid receptor-independent properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000300015

Cannabidiol reduced the striatal atrophy caused 3-nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000300015

Dorsolateral prefrontal cortex N-acetylaspartate/total creatine (NAA/tCr) loss in male recreational cannabis users

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000300015

Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000300015

The marijuana component cannabidiol inhibits beta-amyloid-induced tau protein hyperphosphorylation through Wnt/beta-catenin pathway rescue in PC12 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000300015

Cannabidiol inhibits inducible nitric oxide synthase protein expression and nitric oxide production in beta-amyloid stimulated PC12 neurons through p38 MAP kinase and NF-kappaB involvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000300015

Cannabidiol in vivo blunts beta-amyloid induced neuroinflammation by suppressing IL-1beta and iNOS expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000300015

Nonpsychoactive cannabidiol prevents prion accumulation and protects neurons against prion toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000300015

Delta9 tetrahydrocannabinol and cannabidiol alter cytokine production by human immune cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000300015

The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000300015

Oral anti-inflammatory activity of cannabidiol, a non-psychoactive constituent of cannabis, in acute carrageenan-induced inflammation in the rat paw.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000300015

The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000300015

Post-ischemic treatment with cannabidiol prevents electroencephalographic flattening, hyperlocomotion and neuronal injury in gerbils

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000300015

Cannabidiol prevents infarction via the non-CB1 cannabinoid receptor mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000300015

Cannabidiol prevents cerebral infarction via a serotonergic 5-hydroxytryptamine1A receptor-dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000300015

Repeated treatment with cannabidiol but not Delta9-tetrahydrocannabinol has a neuroprotective effect without the development of tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000300015

Cannabidiol, a nonpsychoactive Cannabis constituent, protects against myocardial ischemic reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000300015

Cannabidiol lowers incidence of diabetes in non-obese diabetic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000300015

Cannabidiol arrests onset of autoimmune diabetes in NOD mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000300015

Neuroprotective and blood-retinal barrier-preserving effects of cannabidiol in experimental diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000300015

Cannabidiol attenuates high glucose-induced endothelial cell inflammatory response and barrier disruption

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000300015

Antiemetic Effect of Delta-9-Tetrahydrocannabinol in Patients Receiving Cancer Chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000300015

Marijuana as antiemetic medicine: a survey of oncologists' experiences and attitudes

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000300015

Cannabidiol, a non-psychoactive component of cannabis and its synthetic dimethylheptyl homolog suppress nausea in an experimental model with rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000300015

Effect of cannabinoids on lithium-induced vomiting in the Suncus murinus (house musk shrew).

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000300015

Delta-9-tetrahydrocannabinol and cannabidiol, but not ondansetron, interfere with conditioned retching reactions elicited by a lithium-paired context in Suncus murinus: An animal model of anticipatory nausea and vomiting

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000300015

The effect of cannabidiol and URB597 on conditioned gaping (a model of nausea) elicited by a lithium-paired context in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000300015

Serum-dependent effects of tamoxifen and cannabinoids upon C6 glioma cell viability

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000300015

Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000300015

Cannabidiol-induced apoptosis in human leukemia cells: A novel role of cannabidiol in the regulation of p22phox and Nox4 expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000300015

Cannabidiol inhibits human glioma cell migration through a cannabinoid receptor-independent mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000300015

Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000300015

Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000300015

Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000300015

The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000300015

The orphan receptor GPR55 is a novel cannabinoid receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000300015

Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000300015

Agonistic properties of cannabidiol at 5-HT1a receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000300015

Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000300015

Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000300015

10.1590/S1516-44462008000300015

21 January 2018

Identifiers

DOI

1 reference

19 August 2017

1 reference